PET/MR Imaging in Lung Cancer

Not Applicable

Terminated

• Conditions: Lung Cancer
• Interventions: Diagnostic Test: PET/MR; Diagnostic Test: PET/CT

• Registration Number: NCT03739281
• Lead Sponsor: University Hospital of North Norway

Brief Summary

The purpose of this project is to investigate if PET/MR imaging improves the accuracy in visualization and characterization of lung cancer disease, compared to PET/CT.

Detailed Description

Lung cancer is the most frequent cancer type and the leading cause of cancer-related death worldwide. Positron emission tomography (PET) coupled with computed tomography (CT) is the standard of care for visualization and staging of lung cancer. Recent clinical introduction of hybrid PET and magnetic resonance (MR) imaging systems has shown potential to improve tumor imaging beyond the limits of PET/CT. However, knowledge about the clinical impact of this new hybrid modality is still limited.

This project aims to investigate how PET/MR may improve the diagnosis and treatment of lung cancer disease, compared to PET/CT: PET/MR may allow early detection of brain and liver metastases, which strongly affects treatment outcome and survival; predictive models based on machine learning may combine image derived biomarkers from PET/MR, histology and health record data, to automatically visualize and characterize the tumor, facilitating computer aided diagnosis and personalized radiotherapy treatment.

Study Timeline

• Study First Submitted: 2018-10-30
• Study First Submitted QC: 2018-11-09
• Study First Posted: 2018-11-13
• Study Start: 2018-12-12
• Primary Completion: 2022-12-31
• Study Completion: 2022-12-31
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-13
• Last Update Posted: 2023-01-17

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

• Referred to clinical PET/CT examination for investigation of lung disease.

Exclusion Criteria

• Blood glucose level >8.3 mmol/l
• MR incompatible objects, e.g. metal implants, inside the body
• Intolerance to gadolinium-based contrast agents, e.g. severe renal disease (GFR<30).
• Unable to give written consent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Nuclear medicine imaging	PET/MR	Patients undergo nuclear medicine imaging with PET/MR and PET/CT.
Nuclear medicine imaging	PET/CT	Patients undergo nuclear medicine imaging with PET/MR and PET/CT.

Primary Outcome Measures

Name	Time	Method
Sensitivity and specificity of PET/MR vs. clinical routine PET/CT	1-2 weeks after the initial inclusion.	Sensitivity and specificity of PET/MR scans will be compared with in clinical routine PET/CT examinations for lung cancer disease feature prediction.

Secondary Outcome Measures

Name	Time	Method
Prediction of treatment response and progression-free survival	5 years after inclusion.	We will investigate which PET/MR or PET/CT features are best suited as an imaging biomarker for treatment response evaluation and for progression-free survival 5 years after inclusion.

Trial Locations

Locations (1)

University Hospital of North Norway; 🇳🇴 Tromsø, Norway